NeuroMetrix, Inc. To Exhibit At American Diabetes Association 75th Scientific Sessions

Quell^™ Wearable Pain Relief and DPNCheck^® Neuropathy Test to be Featured

WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders, reported today that it will exhibit at the American Diabetes Association (ADA) 75^th Scientific Sessions. The ADA Scientific Sessions will be held June 5-9 at The Boston Convention and Exhibition Center in Boston, Massachusetts.

Diabetes is one of the leading causes of chronic pain and nerve disease throughout the world. Diabetes has always been a core market for NeuroMetrix, and continues to represent a major focus for the Company. The ADA Scientific Sessions meeting represents a key opportunity for the Company to engage with thought leaders in the prevention and treatment of diabetes and its complications, and to interact with other companies in the space. Key highlights of the upcoming meeting include:

• Quell^™ will be featured. This over-the-counter wearable device utilizes proprietary non-invasive neurostimulation technology to provide relief for chronic pain. The device is designed for people with conditions such as diabetic nerve pain, which affects over one-quarter of people with diabetes. It is lightweight and can be worn during the day while active, and at night while sleeping. Users have the option of using their smart phone to track and personalize their pain therapy through the Quell Relief app. The Company recently initiated shipments to healthcare professionals and plans full commercialization during June.
• DPNCheck^® will also be featured. This rapid, quantitative and cost effective point-of-care test allows physicians to accurately detect diabetic peripheral neuropathy (DPN), even at very early stages. DPN is the most common complication of diabetes, affecting over half of people with diabetes. DPN causes significant morbidity including loss of sensation, pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations. DPNCheck is directly marketed by NeuroMetrix in the U.S. and by Omron Healthcare in the major markets of Asia.
• The Company’s scientific advisory board, representing international leaders in the detection, management, and treatment of the neurological complications of diabetes, will have its annual meeting.

The following scientific presentations will present new data demonstrating the accuracy and clinical utility of the DPNCheck test.

• Combined Large and Small Fibre Assessments Using Novel Point of Care Devices Provide More Accurate Diagnostic Classification of Diabetic Neuropathy (Poster 636, June 8, 12:00 - 2:00 PM). Study conducted at Sheffield University, UK, in the laboratory of Professor S. Tesfaye.
• Effect of Intensive Weight Reduction on Neuropathy Progression in Patients with Diabetes: A 1-Year Controlled Clinical Trial (Oral Presentation 196, June 7, 4:00 - 4:15 PM). Study conducted at Joslin Diabetes Center, Boston, US, in the laboratory of Dr. O. Hamdy.

Representatives of the Company, including Shai N. Gozani, M.D., Ph.D, President and CEO; Frank McGillin, GM Consumer, Michael MacDonald, SVP Commercial Operations, and Tom Higgins, CFO, will be available for business discussions. Attendees are encouraged to visit NeuroMetrix at booth #1305.

About NeuroMetrix

NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. For more information, please visit www.NeuroMetrix.com.